Details of Disease

General Information of Disease (ID: DIS0IHMD)

• Disease Name: Intestinal amebiasis
• Synonyms: Colitides, amoebic; colitis, amoebic; intestinal Entamoebiases; Colitides, amebic; amebic colitis; amebiasis, intestinal; amoebiasis, intestinal; amoebiases, intestinal; intestinal amebiasis; Entamoebiases, intestinal; amoebic Colitides; dysentery, amoebic; amebic colitides; intestinal Amoebiases; amoebic colitis; intestinal amoebiasis; intestinal Amebiases; entamoebiasis, intestinal; amoebic dysenteries; Amebiases, intestinal; dysenteries, amebic; colitis, amebic; amoebic dysentery; amebic dysenteries; intestinal entamoebiasis; dysenteries, amoebic; amoebic dysentery due to Entamoeba histolytica; amoebiasis due to Entamoeba histolytica; amebic dysentery
• Disease Class: 1A36: Amoebiasis
• Definition: Dysentery caused by intestinal amebic infection, chiefly with entamoeba histolytica. This condition may be associated with amebic infection of the liver and other distant sites.
• Disease Hierarchy:
  DISAJWJL: Amoebiasis
  DISKICS2: Dysentery
  DISOU5FC: Protozoal dysentery
  DIS0IHMD: Intestinal amebiasis
• ICD Code:
  ICD-11: ICD-11: 1A36
  ICD-10: ICD-10: A06, A06.9
  ICD-9: ICD-9: 6
  Expand ICD-9: 6
• Disease Identifiers:
  MONDO ID: MONDO_0024275
  MESH ID: D004404
  UMLS CUI: C0013370
  MedGen ID: 8512
  SNOMED CT ID: 235747003

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Paromomycin	DM1AGXN	Approved	Small molecular drug	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 1 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
IL25	TTVMO5W	Limited	Biomarker	[2]

This Disease Is Related to 5 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
LAMA2	OTFROQWE	Strong	Altered Expression	[3]
MEIS2	OTG4ADLM	Strong	Genetic Variation	[3]
MEOX2	OTKZCJCB	Strong	Genetic Variation	[3]
NR2E1	OTW47GKM	Strong	Genetic Variation	[3]
TFAP2B	OTR1T8E9	Strong	Genetic Variation	[3]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 064171.
• [2] Role of Eosinophils and Tumor Necrosis Factor Alpha in Interleukin-25-Mediated Protection from Amebic Colitis.mBio. 2017 Feb 28;8(1):e02329-16. doi: 10.1128/mBio.02329-16.
• [3] Molecular mechanisms underlying gliomas and glioblastoma pathogenesis revealed by bioinformatics analysis of microarray data.Med Oncol. 2017 Sep 26;34(11):182. doi: 10.1007/s12032-017-1043-x.